Latest news with #YellowCardBiobank
North Wales Live
7 hours ago
- Health
- North Wales Live
Weight-loss jabs linked to multiple deaths as hundreds report problems
Hundreds of individuals have reported pancreas issues associated with weight loss and diabetes injections, leading health officials to launch a study into potential side effects. Some instances of pancreatitis, reportedly connected to GLP-1 medicines (glucagon-like peptide-1 receptor agonists), have resulted in fatalities. The Medicines and Healthcare products Regulatory Agency (MHRA) data reveals that since the licensing of these drugs, there have been hundreds of acute and chronic pancreatitis cases among those taking GLP-1 medicines. This includes: 181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died. 116 reported reactions of this kind linked to liraglutide, one of which was fatal. 113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic (licensed to treat type 2 diabetes) and Wegovy. One person died. 101 reported reactions of this kind linked to exenatide, three people died. 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug. These incidents are not definitively attributed to the medication, but the person who reported them, suspected a possible link. However, the Yellow Card Biobank project, a collaboration between the MHRA and Genomics England, will investigate whether pancreatitis cases linked to GLP-1 drugs could be influenced by genetic factors. The MHRA is urging individuals taking GLP-1 medicine who have been hospitalised due to acute pancreatitis to submit a report to its Yellow Card scheme. Upon receipt of a Yellow Card report, the MHRA will reach out to patients to inquire if they would be willing to participate in the study. Patients are being invited to provide additional details and a saliva sample for examination, which will determine if genetic factors may increase their risk of acute pancreatitis when taking certain medicines. GLP-1 agonists, commonly used to reduce blood sugar levels in people with type 2 diabetes, are also prescribed to aid weight loss for some individuals, reports Wales Online. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. "Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. "Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." Professor Matt Brown, chief scientific officer of Genomics England, said: "GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. We believe there is real potential to minimise these with many adverse reactions having a genetic cause. "This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system."
Scottish Sun
9 hours ago
- Health
- Scottish Sun
Ozempic-like fat jabs taken by millions linked to 181 cases of killer side effect and 5 deaths, health officials warn
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs have been linked to hundreds of people falling ill with a life-threatening illness and 10 deaths, the UK's drug watchdog has warned. Brits have reported falling seriously ill with pancreatitis, a condition where the pancreas becomes inflamed, after taking popular weight loss and diabetes drugs. Sign up for Scottish Sun newsletter Sign up 1 Fresh figures from the UK's medicines regulator reveal more than 560 suspected cases of the illness linked to so-called GLP-1 drugs, which include Mounjaro, Wegovy and Ozempic. At least ten of these cases were fatal, although it's not clear the drugs were directly to blame. The Medicines and Healthcare products Regulatory Agency (MHRA) says the reports have triggered a new investigation into whether people's genes could make them more vulnerable to side effects. Since the drugs were approved for use, 181 cases of pancreatitis have been linked to tirzepatide, the active ingredient in Mounjaro, including five deaths. Another 113 cases have been linked to semaglutide, found in Wegovy and Ozempic, with one fatality. Liraglutide, another weight loss jab, has been tied to 116 suspected cases and one death. Exenatide has been linked to 101 cases, including three deaths, while dulaglutide and lixisenatide have been associated with 63 cases in total, with no known fatalities. The MHRA said these are suspected adverse reactions reported by patients, carers or doctors and there is no firm evidence that the jabs directly caused the deaths. Pancreatitis can also develop in people who don't take these drugs, and is often triggered by gallstones or alcohol. However, regulators believe there could be a genetic link in some patients, and are now launching a study to investigate. The Yellow Card Biobank project, set up with Genomics England, is calling on anyone who has been admitted to hospital with pancreatitis while taking a GLP-1 drug to come forward and provide a saliva sample for analysis. Julia Hartley-Brewer slams government plan for NHS to offer free 'fat jabs' to tackle obesity crisis Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. "Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. "To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. "Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." Pancreatitis is a painful condition that causes severe stomach pain, vomiting and fever. Acute cases usually clear up with fluids and oxygen in hospital, but around five per cent are fatal or cause lasting damage. Despite the risks, experts say the drugs are still safe and effective for most patients. They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes. Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity. But health officials warn they are not a silver bullet and can come with side effects, most commonly nausea, constipation and diarrhoea. The MHRA also recently warned that Mounjaro could reduce the effectiveness of the contraceptive pill in some patients. Professor Matt Brown, chief scientific officer of Genomics England, said: "GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. "We believe there is real potential to minimise these with many adverse reactions having a genetic cause. "This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system."
STV News
10 hours ago
- Health
- STV News
Hundreds of people report pancreas problems linked to weight loss jabs
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects. Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. This includes: – 181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died. – 116 reported reactions of this kind linked to liraglutide, one of which was fatal. – 113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died. – 101 reported reactions of this kind linked to exenatide, three people died. – 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug. These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
ITV News
19 hours ago
- Health
- ITV News
Hundreds of bad reactions linked to weight loss jabs prompts new study
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects. Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions. Dr Alison Cave, MHRA This includes: These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
